Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UBQII
ADC Name
WO2023047090A1-SN-38 reagent (13) ADC
Synonyms
SN-38 reagent (13) ADC
   Click to Show/Hide
Organization
SPIREA LIMITED
Drug Status
Investigative
Drug-to-Antibody Ratio
20.3
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
SN-38 reagent
ADC-specific functional property(2027 Update)
Bystander Killing Effect
Click To Hide/Show 1 ADC-specific functional property Data
Bystander Killing Effect Description Reference
no Undisclosed
[1]
Circulating Stability
Click To Hide/Show 1 ADC-specific functional property Data
Incubation Time 96hours Release 50-55% Reference
[1]
Incubation Medium mouse plasma
Description
ADCs were spiked into mouse plasma and incubated at 37°C over a 96h period. To evaluate thechanges in DAR profile throughout plasma incubation, ADCs were analysed by HIC-UV (214nm)after isolation from plasma using affinity capture.

   Click to Show/Hide
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.04
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.18
nM
CVCL_0033
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.04 nM High HER2 expression (HER2 +++)
Method Description
1250cells/well for SK-BR-3 (100 uL) of cells were seeded onto 384-well plates and incubated for 24 hours before adding the ADC. After 9 hours, the limited exposure treated plates were removed from the incubator and media containing compound was removed. Cells were washed 2x with growth medium and 40 uL growth medium was then added to each well. Plates were incubated at 37 °C/5% CO, for a further 96 hours. 40uL of CellTiter-Glo reagent was added to each well to be tested (the ratio of CellTiter-Glo reagent to medium was 1:1).the plate was then placed at room temperature for 30 minutes, and then reading was carried out on an EnSpire reader for cell counting.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.18 nM High HER2 expression (HER2 +++)
Method Description
1250cells/well for SK-BR-3 (100 uL) of cells were seeded onto 384-well plates and incubated for 24 hours before adding the ADC. After 9 hours, the limited exposure treated plates were removed from the incubator and media containing compound was removed. 40uL of CellTiter-Glo reagent was added to each well to be tested (the ratio of CellTiter-Glo reagent to medium was 1:1).the plate was then placed at room temperature for 30 minutes, and then reading was carried out on an EnSpire reader for cell counting.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
References
Ref 1 Antibody-drug conjugates